Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Supply, Demand and Key Producers, 2023-2029

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Supply, Demand and Key Producers, 2023-2029

The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market size is expected to reach $ 207.3 million by 2029, rising at a market growth of 10.5% CAGR during the forecast period (2023-2029).

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is a growing area focused on developing innovative drugs and treatments to improve the quality of life of patients with PNH. The market covers various treatment options, including monoclonal antibody therapies, immunosuppressive drugs, and hematopoietic stem cell transplantation, aimed at alleviating symptoms, controlling hemolysis, and improving blood abnormalities in PNH patients, thus providing better clinical outcomes. As scientific research continues to advance and medical technology continues to improve, the PNH treatment market is expected to continue to expand, providing patients with more treatment options and the opportunity to improve survival rates.

Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant clonal disease caused by acquired somatic PIG-A gene (phosphotidyl inositol glycan complementation group A) mutations in one or several hematopoietic stem cells. Disease, PIG-A mutation causes abnormal synthesis of glycosyl phosphatidyl inositol (GPI), resulting in the loss of a group of membrane proteins anchored to the cell membrane by GPI, including CD16, CD55, CD59, etc., which are mainly clinically It manifests as chronic intravascular hemolysis, hematopoietic failure and recurrent thrombosis.

This report studies the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment total production and demand, 2018-2029, (K Units)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment total production value, 2018-2029, (USD Million)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment domestic production, consumption, key domestic manufacturers and share

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amoun Pharmaceuticals, EIPICO, Minapharm Pharmaceuticals, Pharco Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Akari Therapeutics, Amgen and CSL Behring, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation by Type
Monoclonal Antibodies Therapy
Immunosuppressive Drugs
Hematopoietic Stem Cell Transplantation

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Segmentation by Application
Hospital
Clinic
Other

Companies Profiled:
Amoun Pharmaceuticals
EIPICO
Minapharm Pharmaceuticals
Pharco Pharmaceuticals
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ
F. Hoffmann-La Roche Ltd
Novartis AG
Amgen Inc
Teva Pharmaceutical
Abbott

Key Questions Answered

1. How big is the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?

2. What is the demand of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?

3. What is the year over year growth of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?

4. What is the production and production value of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?

5. Who are the key producers in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?